Clinical Laserthermia Systems AB (publ) announced that a new patent application for expanded and extended protection for the company's technology has been filed. The current patent for CLS non-cooled laser applicators is valid until 2036 and has its origins in a collaboration that CLS initiated in 2010 with the German laser technology company Laser- und Medizin-Technologie GmbH, LMTB, regarding fiber development. In 2017, CLS purchased parts of LMTB and secured access to LMTB's patents and know-how for the unique diffuser technology.

CLS diffuser-type laser applicator makes it possible to treat larger cancer tumors, without cooling the laser applicator like the company?s competitors, and is part of the company's extensive portfolio of laser applicators and instruments that, together with the mobile laser unit and MRI thermometry software, form the core of CLS's technology platform. The new patent application is an important part of the work to create and protect CLS's intellectual property rights, which are valuable assets in the company. Based on new knowledge from the company?s clinical activities in the US and at Skåne University Hospital, the CLS non-cooled laser applicator has been improved through new inventions that CLS believes are patentable.

If the patent application is approved, protection is provided for the new inventions until 2044.